226 related articles for article (PubMed ID: 11583066)
21. Current approved options for treating patients with multiple sclerosis.
Rizvi SA; Agius MA
Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulation by the copolymer glatiramer acetate.
Arnon R; Sela M
J Mol Recognit; 2003; 16(6):412-21. PubMed ID: 14732933
[TBL] [Abstract][Full Text] [Related]
23. Glatiramer acetate.
Comi G; Moiola L
Neurologia; 2002 May; 17(5):244-58. PubMed ID: 12031214
[TBL] [Abstract][Full Text] [Related]
24. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
[TBL] [Abstract][Full Text] [Related]
25. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
26. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
Chen M; Gran B; Costello K; Johnson K; Martin R; Dhib-Jalbut S
Mult Scler; 2001 Aug; 7(4):209-19. PubMed ID: 11548979
[TBL] [Abstract][Full Text] [Related]
27. Copolymer 1 from the laboratory to FDA.
Teitelbaum D; Sela M; Arnon R
Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880
[No Abstract] [Full Text] [Related]
28. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
29. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
Filippi M; Wolinsky JS; Comi G;
Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
[TBL] [Abstract][Full Text] [Related]
30. Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players.
Van Kaer L
Exp Neurol; 2011 Jan; 227(1):19-23. PubMed ID: 20969865
[TBL] [Abstract][Full Text] [Related]
31. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
32. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.
Teitelbaum D; Brenner T; Abramsky O; Aharoni R; Sela M; Arnon R
Mult Scler; 2003 Dec; 9(6):592-9. PubMed ID: 14664472
[TBL] [Abstract][Full Text] [Related]
33. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
34. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
Weinstein A; Schwid SR; Schiffer RB; McDermott MP; Giang DW; Goodman AD
Arch Neurol; 1999 Mar; 56(3):319-24. PubMed ID: 10190822
[TBL] [Abstract][Full Text] [Related]
36. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
37. Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.
Rovaris M; Codella M; Moiola L; Ghezzi A; Zaffaroni M; Mancardi G; Capello E; Sardanelli F; Comi G; Filippi M
Neurology; 2002 Nov; 59(9):1429-32. PubMed ID: 12427898
[TBL] [Abstract][Full Text] [Related]
38. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
39. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Schrempf W; Ziemssen T
Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
[TBL] [Abstract][Full Text] [Related]
40. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
